Our pipeline consists of new and emerging, non-opioid pain therapies aimed at selectively interrupting pain transmission pathways to more effectively treat moderate to severe chronic pain without risks of dependence or abuse.
We are studying our therapies in companion animals with the same naturally-occurring, pain-causing disease conditions that are common to both humans and animals. By validating the safety and therapeutic effect of our treatments in both humans and animals, we are able to work on parallel tracks to develop human and veterinary treatments.
Capsaicin is a naturally-occuring compound found in chili peppers that has been safely used as a spice and medicine for centuries. Capsaicin has been used as an over-the-counter topical analgesic for decades, to provide temporary relief from mild-to-moderate pain associated with common conditions including osteoarthritis and neuropathic pain.
Our STRATI® technology (Synthetic TRans cApsaicin ulTra-pure Injection), is a selective, highly potent, ultrapure, synthetic form of trans-capsaicin that is injected directly into the site of pain. It harnesses the natural analgesic power of capsaicin to develop a proprietary injectable therapy designed to provide fast-acting, long-lasting and targeted pain relief.
Our lead therapeutic candidate, CNTX-4975, is based on our STRATI technology. CNTX-4975 is being evaluated for the treatment of osteoarthritis pain of the knee in humans and canines, as well as in patients with Morton’s neuroma, a rare, painful foot condition.
STRATI works by targeting the TRPV1 receptor that selectively inactivates the local pain fibers transmitting pain signals to the brain, potentially providing relief that can last for up to six months, until the local pain fibers regenerate. Through its targeted delivery and highly selective method of action, CNTX-4975 manages pain without disrupting other nerve functions.
We recently announced results from our TRIUMPH trial, a randomized, double-blind, placebo-controlled, multicenter Phase 2b clinical trial, in patients with chronic moderate to severe pain due to knee osteoarthritis. On the trial, patients were given a single injection of CNTX-4975, and results showed a rapid and highly statistically significant reduction in pain that occurred within days and lasted at least six months. Twenty-two percent of patients achieved a 90 percent or greater reduction in pain and 67 percent of patients achieved 50 percent or greater reduction in pain.
In a Phase 2a study in patients with Morton’s neuroma, treatment with CNTX-4975 resulted in a statistically significant reduction of pain within days. The pain relief persisted until the last time point measured at four weeks post-injection. CNTX-4975 has Orphan Drug and Fast Track designations from the U.S. FDA.
How CNTX-4975 Works
TRPV1 expressing neurons after exposure to capsaicin.
Source: Man-Kyo Chung UMD 2015
CNTX-2022 is a proprietary, high concentration (40%) topical gel formulation of lidocaine. It has the potential to be used to address pain across a broad range of indications including superficial musculoskeletal pain, neuropathic pain and dermatologic pain/discomfort.
BUILDING A PAIN POWERHOUSE
Through strategic in-licensing, we acquired three promising analgesics from Boehringer Ingelheim’s research and discovery portfolio, each one with a promising, unique profile for the treatment of chronic pain.
CNTX-6970 is a novel, potent and selective CCR2 antagonist with a unique analgesic profile. Recent studies have shown a close link between chronic pain and the immune system. CNTX-6970 capitalizes on this connection by taking a novel “neuro-immune” approach. The compound has a dual effect: stopping immune cells from releasing the potent cytokine CCL2 and stopping CCL2 from stimulating pain fibers to send pain signals. Based on our extensive big data analytics and research, CNTX-6970 is predicted to be well suited to treat chronic painful inflammatory conditions such as osteoarthritis. CNTX-6970 is in development to treat inflammatory pain and data to date have shown that CNTX-6970 is safe and well tolerated and has demonstrated pharmacologic activity evidenced by target engagement.
CNTX-6016 is the first of the new generation, potent and “super selective” cannabinoid CB2 agonists. It is 20,000 times more selective for the CB2 receptor than the CB1, and thereby able to achieve pain relief without psychotropic and other side effects seen with less selective agonists. Based on our big data analytics and research, it looks most promising in neuropathic pain models, and is well suited to treat chronic painful conditions such as diabetic neuropathic pain.
CNTX-0290, a first-in-class, potent and selective somatostatin receptor type 4 (SSTR4) agonist, is a completely novel pain target that can be applied to a broad range of chronic pain types. CNTX-0290 works by activating the SSTR4 receptor, which functions as a “master control” switch to turn down the activity of several other pain receptors, such as specific calcium channels, potassium channels and TRPV1 and TRPA1 channels, thereby reducing the transmission of pain signals. CNTX-0290 has shown activity in every chronic pain model it has been tested in to date. Based on our big data analytics, we believe it has promise in treating a wide variety of chronic pain conditions and could be especially valuable for mixed pain, such as chronic back pain.